DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

The purpose of this study, known as DISCERN, is to compare two different treatments for a type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker known as PD-L1. This study will help us understand if using two types of immune therapy together with chemotherapy is better than using one type of immune therapy with chemotherapy. We're doing this by looking at changes in the subject's cancer's DNA in the blood after starting treatment.

Trial Details

NCT ID

NCT06364917

Phase

PHASE2

Sponsor

University of Alabama at Birmingham

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

Pembrolizumab
Carboplatin
Paclitaxel
Pemetrexed
Nivolumab
Ipilimumab

Locations (sample)

Birmingham, Alabama, United States|33.52066,-86.80249

Key Eligibility Criteria

Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Male or female aged 18 years or older.
Participants must have histologically or cytologically confirmed non-small cell lung cancer which is stage IV

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →